Patients with Glycogen storage disease type I may develop hepatocellular adenoma, a recognised complication that requires a structured management approach. The initial clinical question is whether conservative intervention can achieve lesion regression without escalation.
The presence of hepatocellular adenoma in this population shapes the treatment strategy from the outset. Initial management is conservative, with metabolic optimisation as the central objective alongside close monitoring of adenoma behaviour.
The first-line strategy incorporates a conservative framework that combines watchful waiting with optimisation of metabolic control. Under this approach, regression of adenomas is a recognised outcome — the complete structured regimen, its components, and clinical decision points are detailed in the full protocol.
The primary treatment target in this setting is regression of adenomas.
DOI: 10.1038/gim.2014.128
Initially, the management of liver adenomas in the GSD I population should be conservative (Box 3).
An approach of watchful waiting may be used.
Adenomas are often multiple. In some situations, there is regression of adenomas noted with good metabolic control.
View source ↗